Skip to main content
. 2021 May 5;99(8):1033–1042. doi: 10.1007/s00109-021-02080-4

Fig. 2.

Fig. 2

Ligand binding to surface receptor (e.g. EGF-R) evokes downstream signaling leading to MAPKERK activation. b The introduction of BRAFV600E in mouse microglia leads to substantial overactivation of MAPKERK. This resulted in clinical and histopathological substantial neurodegeneration. c Early administration of BRAFV600E-inhibiting PLX4720 to these mice with BRAFV600E expressing microglia gave diminished MAPKERK activation in these microglia and clinically as well as histopathologically attenuated neurodegeneration [5]